Opticyte is transforming care for the leading causes of organ failure, including sepsis, with real-time measurements.
Opticyte, Inc, a medical device innovator developing proprietary advanced algorithms and tailored optical spectroscopy technology to measure and detect low oxygen levels in cells to prevent organ failure. Opticyte is developing the first Cell O2 Monitor for reducing organ failure. Founded in 2016, Opticyte, Inc, is a spinoff from the University of Washington. Headquartered in Seattle, WA, Opticyte employs engineering, regulatory, and communications teams with deep experience in bringing medical devices to market.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 1, 2016 | Grant | $1.10M | 1 | National Institutes of Health | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Institutes of Health | Yes | Grant |